1-2 of 2
Karolyn K. Morris, BA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ryan C. Lynch, MD, Ryan D. Cassaday, MD, Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Edus H. Warren, MD PhD, Mazyar Shadman, MDMPH, Andrei R Shustov, MD, Brian G. Till, MD, Chaitra S. Ujjani, MD, Edward Libby, MD, Mary Philip, MDPhD, Hilary Coye, PA-C, Christen N. Martino, NP, Sandra Kanan, MSN, ARNP, Karolyn K. Morris, BA, Heather A. Rasmussen, BS, Sanaz Behnia, MD, Margaret E. Nartea, BS, Jenna M. Voutsinas, MPH, Ajay K. Gopal, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-133763
Published: 2020
Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1596.
https://doi.org/10.1182/blood-2019-126086
Published: 2019